Many studies have linked myeloperoxidase (MPO), a neutrophil and inflammatory marker, to cardiac inflammation in the setting of acute coronary syndrome (ACS).
Prior studies reported that Myeloperoxidase and Galectin-3, which are biomarkers of coronary plaque vulnerability, are elevated in acute coronary syndrome (ACS) patients.
We found no relationship between elevated levels of MPO activity post-acute coronary syndrome and mortality up to 7-years of follow-up in the ERICO study.
Graphical abstract A trimetallic CuPdPt nanowire networks was placed on a glassy cabon electrode (GCE) to design an immunosensor for myeloperoxidase (MPO), a biomarker for the acute coronary syndrome (ACS).
As myeloperoxidase is a prognostic marker of coronary events, the MAPK14 variant may provide a mechanistic link between p38 map kinase and these events, providing information consistent with current indication of Losmapimod for acute coronary syndrome.
Increased plasma myeloperoxidase concentrations are linked to coronary artery stenosis and may be useful for risk prediction following acute coronary syndromes.